RESEARCH COMMUNICATION

Metaplastic Carcinoma of the Breast, an Intriguing Rarity

Fozia Rauf, Naila Kiyani, Yasmin Bhurgri*

Abstract

Metaplastic carcinoma of the breast is categorized as a rare heterogeneous neoplasm generally characterized by a mixture of adenocarcinoma with dominant areas of spindle cell, squamous and/or other mesenchymal differentiation. To determine the epidemiological and histopathological characteristics of this rare entity a retrospective study was conducted to review all cases at the Aga Khan University Hospital (AKUH) Karachi, received during 1st January 2000 to 31st August 2005. Twenty-four patients were identified with a mean age at diagnosis of 46.4 (±SD 3.8) years, and an age range of 28-68 years. The mean tumor size was 7.9 cm, range 2.0-17.0 cms (±SD 4.77). The specimens were mostly obtained by modified radical mastectomy (54.2%) followed by biopsy (29.2%), lumpectomy (8.3%), and total mastectomy (4.2%). Skin ulceration was found in 37.5% cases. Component sub-categorization showed 13 (54.2%) cases of infiltrating ductal carcinoma with squamous metaplasia, followed by 2 (8.3%) cases with heterologous elements, 4 (16.7%) cases with spindle cell component, 2 cases of matrix producing carcinoma and one case of squamous cell carcinoma. The malignancy was high grade, modified Bloom Richardson’s grade III (54.2%) and grade II (12.5%). Such grading was not applicable to 4 cases of spindle cell component and 1 case with extensive chondroid areas. Twelve patients had information available on the nodal status. Five (41.6%) were node-negative, four (33.33%) had 1-3 lymph node involvement positive, and three (12.5%) had more than 3 lymph nodes positive. The median 3 year Event Free Survival (EFS) was 10% and overall survival was 30%. MCB is an aggressive disease with a poor prognosis. This aspect appears bleaker in our population either due to the biological characteristic of the malignancy in a high risk group or the lack of availability and accessibility of health coverage, resulting in a delayed presentation. MCB is an uncommon breast malignancy and due to the lack of sufficiently large studies there is limited knowledge as to the pathogenesis, progress, best treatment protocols and prognosis. Collaborative studies are therefore recommended to allow for better understanding of this intriguing neoplasm.

Key Words: Metaplastic carcinoma breast - characteristics - Pakistan

Introduction

Benign and malignant tumors of the breast predominantly arise from glandular epithelium. In some cases, however, glandular epithelium differentiates into non-glandular mesenchymal tissue, a process termed metaplasia (Brenner et al., 1998). Pathogenesis of such diverse elements has been the subject of much controversy.

Metaplastic changes in the breast include squamous cell, spindle cell, and heterologous mesenchymal growth and occur in fewer than 5% of breast carcinomas (Wargotz and Norris, 1989a; 1989b; 1990a; 1990b; Wargotz et al., 1989; Pitts et al., 1991). Carcinosarcomas, a subgroup of metaplastic carcinomas, are the rarest primary malignancies of the breast, found in < 0.1% of cases (Feder et al., 1999). Wargotz and Norris (1989a; 1989b and 1990a) and Wargotz et al (1989) categorized metaplastic carcinoma breast (MCB) into four variants which included matrix-producing carcinoma, spindle cell carcinoma, squamous cell carcinoma, and carcinosarcoma. Earlier, Oberman in 1987 had suggested that all such tumors be categorized as metaplastic carcinoma of the breast (MCB), de-emphasizing whether the metaplastic component is of mesenchymal or epithelial origin. Subsequently, after the advent of immunohistochemistry, it was generally accepted that metaplasia of the epithelial elements of a carcinoma gives MCB a pseudosarcomatous appearance. Hence the name is given to malignant breast neoplasms which show cytokeratin positivity in both epithelial and mesenchymal elements (Saxena et al., 2004). At present, MCB is considered a rare heterogeneous group of neoplasms ranging from tumors with a predominant component of overt carcinoma and focal mesenchymal differentiation to keratin-positive tumors with pure sarcomatoid morphology (Davis et al., 2005).

Morphologically, the malignancy is characterized by an intimate admixture of epithelial and mesenchymal elements in variable combinations. MCB encompasses epithelial only carcinoma (high grade adenosquamous carcinoma or pure...
Fozia Rauf et al.

and also second opinion slides. Patients were identified cases primarily diagnosed at AKUH pathology department. This included cases from January 2000 to August 2005.

Materials and Methods

This retrospective descriptive study was carried out at the Aga Khan University Hospital (AKUH) pathology department. All consecutive cases of MCB (ICD-O-3 categories M-8575) diagnosed during the last decade (1st January 2000 to 31st August 2005) in the section of histopathology were reviewed for the study. This included cases primarily diagnosed at AKUH pathology department and also second opinion slides. Patients were identified through the AKUH pathology archived data using SNOMED code. Originally all specimens had been fixed in 10% buffered formalin, grossed and representative sections taken according to established protocols. The sections had been routinely processed under standardized conditions for paraffin embedding. The sections had been cut and stained with hematoxylin and eosin (H&E) using a standard format incorporating all the relevant parameters. The cases had been evaluated and diagnosed after consensus interpretation of slides. For the present study, archived microscopic slides were reviewed by a pathologist who was a breast pathology specialist. Immunohistochemical analysis was performed in 9 cases by employing the envision technique. The mixed cell origin of MCB was corroborated by histopathologic staining for mesenchymal cells (vimentin), epithelial cells (cytokeratin), and myoepithelial cells (S-100 protein, actin, and high-molecular-weight cytokeratin).

Clinical information, pathologic size, morphological findings, and lymph node status were obtained from the surgical pathology reports. Variables recorded were the hospital patient-number, date of incidence, name, age, sex, address, topography, morphology, grading and staging. All morphological and biological types were included; there were no exclusion criteria within the diagnosis of MCB. Cases were categorized by the age of the patient, morphological and biological presentation of the tumor. The information taken from archived reports was rechecked and survival status established. The data were analyzed using SPSS 13.0.

The pathology department of AKUH receives surgical specimens from AKUH, Karachi and through 84 pathology laboratory collection points in Pakistan. It covers a large geographical area, with collection points located in all major cities like Karachi, Hyderabad, Multan, Lahore, Quetta, Peshawar, Islamabad, Rawalpindi, Larkana and also many rural locations. Quality control for diagnostic pathology is maintained through internal and external quality checks. External quality assurances for diagnostic pathology are maintained by the College of American Pathologists (CAP) surveys. Internal quality assurances are maintained by the use of histochemical stains, immunohistochemical techniques. Biological markers are used for malignancies, which necessitates cellular typing and sub typing. The departmental consensus committee confirms diagnosis.

Results

Twenty four cases of MCB received over a five year 8 month period were analyzed. All patients were women, with an age range of 28-68 years. The mean age at diagnosis was 46.4 (±SD 3.8) years and the median age was 49 years. The presenting complaint was a rapidly growing palpable breast mass. No patient reported a familial risk factor for breast cancer.

The surgical specimens were obtained for diagnostic assessment by modified radical mastectomy (MRM) in 13
(54.2%) cases, core biopsy in 7 (29.2%), breast conserving surgery in (BCS), lumpectomy in 2 (8.3%) and total mastectomy in 1 (4.2%). In the one (4.2%) second opinion case, the mode of surgery was not specified.

On gross examination skin was ulcerated in 9 (37.5%) cases, normal in 9 (37.5%) and in 6 (25.0%) skin was neither available as part of the specimen, nor clinical information available, so that skin involvement could not be commented on. The tumor was observed on the left side in 12 (50%) cases, on the right side in 5 (20.8%) cases. Laterality was not known in 7 (29.2%) cases. The exact size of the tumor was available in 16 cases with range of 2-17 cms and a mean and standard deviation of 7.9 ± 4.77.

Component sub-categorization showed 14 (58.4%) cases of infiltrating ductal carcinoma with squamous metaplasia, 5 (20.8%) with spindle cell components, 2 (8.3%) with heterologous elements, 2 (8.3%) of matrix producing carcinoma, and one of squamous cell carcinoma (4.2%).

Immunochemistry as a diagnostic tool was essential in 5 cases with spindle cell components, 2 with heterologous elements and 2 of matrix producing carcinoma. Vimentin and cytokeratin were positive in all 9 cases, S100 protein was positive in 2 of the 5 cases in which it was used and smooth muscle actin was positive in 1 out of the 6 cases in which it was used.

Modified Bloom Richardson grading was used to grade 16 cases. Thirteen (54.2%) cases were grade III and 3 (12.5%) cases were grade II. Modified Bloom Richardson grading was not possible in 8 high grade cases, 5 cases of vimentin positive spindle cell type (see Figure 1a), 2 cases of matrix producing carcinoma, and one case of squamous cell carcinoma. Lymph nodes were recovered in 12 of the 13 cases of MRM. In 5 (41.6%) cases lymph node metastasis was not present. In 4 (33.3%) cases 1-3 lymph nodes were involved (N1) and in 3 cases (25.0%) more than 3 lymph nodes were involved (N2).

The tumor margin was positive in 2 (14.2%) of the 14 cases of MRM and total mastectomy. The margin was close, within or <5 mm in 4 (28.57%) cases and free in 8 (57.1%) cases. Estrogen receptor studies were available in 10 (41.6%) cases which were all negative. Progesterone receptor studies were available in 7 (29.16%) cases and were negative in 6 (85.7%) cases. The median 3 year event free survival (EFS) was 10% and overall survival was 30%.

Discussion

MCBs are regarded as ductal carcinomas that undergo metaplasia into a nonglandular growth pattern (Brenner et al., 1998; Wargotz et al., 1989). Due to the rarity of the disease, published work is limited to mostly single case reports (Alam et al., 2003; Greenberg et al., 2004) or a few small series (Al Sayed et al., 2006; Carter et al., 2006; Dave et al., 2006; Davis et al., 2005; Kuo et al., 2000; Chao et al., 1999) thus restricting comparisons. The prognostic criteria used to determine MCB aggressiveness are age of occurrence, stage of the disease, size of the lesion, lymph node status, histologic type and grade and the grade of the mesenchymal component. On the basis of these criteria of comparison, it is our observation that the MCB in the present study and largely in Asia is a more aggressive disease.

Most western studies cite an older age group involvement by MCB, which is reportedly more common in women above 50 years of age (Pitts et al., 1991; Wargotz and Norris, 1989; 1990; Oberman, 1987; Taylor et al., 1994). Carter et al in 2006 reviewed 29 cases of MCB in the United States. The patients in their series were older then in ours series, with a median age of 68 years and a range of 40 to 96 years. In comparison MCB presents in a younger age group in Asians. In different Asian settings, the median age of presentation reported was 52.5 years in a series of 8 patients (Kuo et al, 2000), 50.5 years in a series of 14 cases (Chao et al, 1999), 48.0 years in a series of 19 patients (Al Sayed et al, 2006) and 49.0 years in the present series of 24 patients.

The size of the malignancy at diagnosis is a reflection of rapid growth and biological behaviour of the tumour, or a

Figure 1. Spindle Cell Metaplastic Carcinoma of the Breast a) H&E, b) Vimentin Staining
late presentation, due to a lack of availability or accessibility of health facilities. All factors may be at play in our environment. A comparison of international studies is given in Table 1. MCB at presentation appears not only as a larger tumour in Asians but also exhibits a higher potential for metastasis. In the US, however a positive lymphnode status is less usual. MCBs are usually well-circumscribed lesions but 37.5% of our patients presented with an ulcerated mass which is an unusual finding, highlighting the late presentation of patients with breast malignancy in developing countries. This was also reported by Alam et al from India in 2003. The ER, PR and HER-2 status is overwhelmingly negative, which minimises the options for adjuvant treatment in patients with advanced disease (Leibl and Moinfar, 2005).

Grades are higher and survival is very much lower in Asian than in American patients. Unfortunately the survival in our cases is the lowest reported. This aspect appears bleaker in our population either due to the biological characteristic of the malignancy in a high risk group or the lack of availability and accessibility of health coverage, resulting in a delayed presentation. MCB is an uncommon breast malignancy and the lack of sufficiently large studies there is limited knowledge of the pathogenesis, progress, best treatment protocols and prognosis of the disease. Collaborative studies are therefore recommended to allow for better understanding of this intriguing rarity.

**References**


Leibl S, Moinfar F (2005). Metaplastic breast carcinomas are

---

**Table 1. Comparison of Characteristics for Metaplastic Carcinoma of the Breast in Different Series**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>24</td>
<td>19</td>
<td>34</td>
<td>27</td>
<td>29</td>
<td>100</td>
<td>43</td>
</tr>
<tr>
<td>Duration of study; years</td>
<td>5(+8 months)</td>
<td>10</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Age (median); years</td>
<td>49</td>
<td>48</td>
<td>-</td>
<td>59</td>
<td>68</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Range</td>
<td>-</td>
<td>14-58</td>
<td>-</td>
<td>39-90</td>
<td>40-96</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Size (median); cms</td>
<td>6.5</td>
<td>9.0</td>
<td>3.4</td>
<td>4.0</td>
<td>3.4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Range</td>
<td>2-17</td>
<td>3-18</td>
<td>5.7-10</td>
<td>1.5-15</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lymph node status, +</td>
<td>7/12</td>
<td>-</td>
<td>3/23</td>
<td>-</td>
<td>34</td>
<td>25%</td>
<td>-</td>
</tr>
<tr>
<td>Distant metastases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Estrogen receptor +</td>
<td>0%</td>
<td>11%</td>
<td>9%</td>
<td>13%</td>
<td>-</td>
<td>-</td>
<td>9%</td>
</tr>
<tr>
<td>High MBRC grade</td>
<td>13/16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stage II</td>
<td>-</td>
<td>8/19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stage III</td>
<td>-</td>
<td>9/19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stage IV</td>
<td>24</td>
<td>2/19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Median event free survival (EFS)</td>
<td>10%</td>
<td>15%</td>
<td>-</td>
<td>40%</td>
<td>27.6%</td>
<td>94%</td>
<td>-</td>
</tr>
<tr>
<td>Overall survival (OS)</td>
<td>20%</td>
<td>48%</td>
<td>-</td>
<td>71%</td>
<td>42%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Median event free survival (EFS)</td>
<td>3 years</td>
<td>3 years</td>
<td>3 year</td>
<td>29.5 mths.</td>
<td>74 mths.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Overall survival (OS)</td>
<td>3 years</td>
<td>3 years</td>
<td>3 year</td>
<td>11.5 mths.</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol, 58, 700-4.


